CELLASTRA INC
"Switch on" natural scarless healing in
Long COVID,
Surgery & Burn Care
CELLASTRA NEWS
CELLASTRA INC.
02/06/2024
Cellastra Receives US Patent for Recombinant Gene Vectors Encoded to Regulate Endogenous Production of Anti Scarring/Adhesion Lactoferrin Biomolecules
San Francisco, CA, February 06, 2024. Cellastra Inc. (Cellastra or “the Company”), a developer of novel gene therapy assets, announced today, that the company has been granted US Patent No. 11,891,429, entitled “Methods for regulating endogenous production of lactoferrin and subpeptides thereof.” The patent claims describe a r ecombinant virus vector (RVV) comprising a nucleotide sequence encoding a human lactoferrin protein or a sub-peptide thereof,,,
CELLASTRA INC.
12/26/2023
Cellastra appoints Brad
Thompson to Chair, Scientific
Advisory Board (SAB), and
Karl Mettinger to Chair (Interim),
Board of Directors. LINK
CELLASTRA INC.
08/23/23
Cellastra strategic report
on gene therapy
CELLASTRA INC.
07/07/2023
